Logo image of ESLA

ESTRELLA IMMUNOPHARMA INC (ESLA) Stock Fundamental Analysis

NASDAQ:ESLA - Nasdaq - US2975841048 - Common Stock - Currency: USD

1.13  -0.03 (-2.59%)

Fundamental Rating

1

ESLA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 563 industry peers in the Biotechnology industry. While ESLA seems to be doing ok healthwise, there are quite some concerns on its profitability. ESLA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ESLA has reported negative net income.
ESLA had a negative operating cash flow in the past year.
In the past 5 years ESLA always reported negative net income.
ESLA had a negative operating cash flow in each of the past 5 years.
ESLA Yearly Net Income VS EBIT VS OCF VS FCFESLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -236.08%, ESLA is doing worse than 92.01% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1181.55%, ESLA is doing worse than 83.30% of the companies in the same industry.
Industry RankSector Rank
ROA -236.08%
ROE -1181.55%
ROIC N/A
ROA(3y)-58.33%
ROA(5y)N/A
ROE(3y)-61.93%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESLA Yearly ROA, ROE, ROICESLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ESLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ESLA Yearly Profit, Operating, Gross MarginsESLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ESLA has more shares outstanding
There is no outstanding debt for ESLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ESLA Yearly Shares OutstandingESLA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
ESLA Yearly Total Debt VS Total AssetsESLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ESLA has an Altman-Z score of -8.40. This is a bad value and indicates that ESLA is not financially healthy and even has some risk of bankruptcy.
ESLA has a worse Altman-Z score (-8.40) than 71.05% of its industry peers.
There is no outstanding debt for ESLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.4
ROIC/WACCN/A
WACCN/A
ESLA Yearly LT Debt VS Equity VS FCFESLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 0.75 indicates that ESLA may have some problems paying its short term obligations.
ESLA's Current ratio of 0.75 is on the low side compared to the rest of the industry. ESLA is outperformed by 91.47% of its industry peers.
ESLA has a Quick Ratio of 0.75. This is a bad value and indicates that ESLA is not financially healthy enough and could expect problems in meeting its short term obligations.
ESLA has a Quick ratio of 0.75. This is amonst the worse of the industry: ESLA underperforms 91.30% of its industry peers.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.75
ESLA Yearly Current Assets VS Current LiabilitesESLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 87.46% over the past year.
EPS 1Y (TTM)87.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 77.03% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-132.85%
EPS Next 2Y-94.85%
EPS Next 3Y-67.6%
EPS Next 5Y77.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ESLA Yearly Revenue VS EstimatesESLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
ESLA Yearly EPS VS EstimatesESLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ESLA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ESLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESLA Price Earnings VS Forward Price EarningsESLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ESLA Per share dataESLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A cheap valuation may be justified as ESLA's earnings are expected to decrease with -67.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-94.85%
EPS Next 3Y-67.6%

More info and screens

0

5. Dividend

5.1 Amount

ESLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESTRELLA IMMUNOPHARMA INC

NASDAQ:ESLA (5/5/2025, 8:06:33 PM)

1.13

-0.03 (-2.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.81%
Inst Owner Change-0.16%
Ins Owners2.22%
Ins Owner Change0%
Market Cap40.88M
Analysts82.86
Price Target16.32 (1344.25%)
Short Float %0.02%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 54.78
P/tB 54.78
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -236.08%
ROE -1181.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.33%
ROA(5y)N/A
ROE(3y)-61.93%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.75
Altman-Z -8.4
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.75%
EPS Next Y-132.85%
EPS Next 2Y-94.85%
EPS Next 3Y-67.6%
EPS Next 5Y77.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-233.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1318.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1318.16%
OCF growth 3YN/A
OCF growth 5YN/A